|開催日時：||2017年7月20日 12：00 ～ 13：00|
|講師：||Helen E Heslop|
|所属：||Professor Departments of Medicine and Pediatrics Section of Hematology-Oncology, Director - Center for Cell and Gene Therapy Baylor College of Medicine|
|演題：||Adoptive transfer of virus-specific T cells|
Viral infections are still a major complication during the period of immune suppression that follows allogeneic hematopoietic stem cell transplantation (HSCT). Adoptive transfer of donor-derived virus-specific cytotoxic T cells (VSTs) is a strategy to rapidly restore virus-specific immunity to prevent or treat viral diseases after HSCT that was initially reported in 1992 in CMV infection. Since then multiple studies using different expansion or direct selection techniques have shown that donor-derived VSTs confer protection in vivo after adoptive transfer in 70% to 90% of recipients with CMV or adenovirus infections and EBV lymphoproliferation. Because a major cause of failure is lack of immunity to the infecting virus in a naïve donor, more recent studies have infused closely matched third-party VSTs and reported encouraging response rates between 50 and 90%. Current efforts are investigating broadening the applicability of this approach by simplifying manufacture, extending the number of viral antigens being targeted and optimizing “off the shelf” approaches. Most importantly there are several late phase trials underway that will hopefully move this strategy to standard of care.
|世話人：||〇東條 有伸 （分子療法分野）
四柳 宏 （感染症分野）